Recruitment completed in investigator-sponsored Phase 1 Fabry study Phase 1 and Phase 2 clinical data updates for AVR-RD-01 in Fabry disease reported at WORLDSymposium 2019 Clinical trials in Gaucher and cystinosis expected to start in 2019 Introduced plato™ platform for worldwide gene therapy
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- AVROBIO, Inc . (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the Cowen and Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019 , at 8:40 a.m.
All patients with reported data exhibit AGA enzyme activity above the diagnostic range for males with classic Fabry disease after receiving AVR-RD-01, including at 22 months for Patient 1 in the Phase 1 study Impact of gene therapy on substrate and metabolite levels observed both in patients who